MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Zotiraciclib

CAS No. : 1204918-72-8

MCE 站：Zotiraciclib

产品活性：Zotiraciclib (TG02; SB1317) 是一种有效的 CDK2，JAK2 和 FLT3 抑制剂，IC₅₀ 分别为 13，73 和 56 nM。

研究领域：Cell Cycle/DNA Damage  |  JAK/STAT Signaling  |  Epigenetics  |  Stem Cell/Wnt  |  Protein Tyrosine Kinase/RTK

作用靶点：CDK  |  JAK  |  FLT3

In Vitro: Zotiraciclib (SB1317) has a highly novel kinase inhibitory spectrum inhibiting 17 kinases from a panel of 63, 11 of which are CDK/JAK/FLT family members. The others, Lck, Fyn, Fms, TYRO3, ERK5, and p38δ, are implicated in inflammatory and proliferative processes. Human CYP1A2, 3A4, 2C9, and 2C19 isoforms are not inhibited by Zotiraciclib at the highest tested concentration of 25 μM, but Zotiraciclib inhibits CYP2D6 with IC₅₀=0.95 μM, approximately at the plasma C_max observed at the maximum tolerated dose. Zotiraciclib inhibits cell proliferation concentrations in HCT-116 (IC₅₀=0.079 μM) and HL-60 (IC₅₀=0.059 μM). Zotiraciclib (SB1317) is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib is mainly metabolized by CYP3A4 and CY1A2 in vitro. Zotiraciclib does not inhibit any of the major human CYPs in vitro except CYP2D6 (IC₅₀=1 μM). Zotiraciclib does not significantly induce CYP1A and CYP3A4 in human hepatocytes in vitro.

In Vivo: Treatment with Zotiraciclib (SB1317) at 75 mg/kg po q.d. 3×/week significantly inhibits the growth of tumors with a mean TGI of 82%, while the lower dose of 50 mg/kg po 3×/week is marginally effective. Treatment with Zotiraciclib using either regime significantly inhibits the growth of tumors with mean TGIs of 42% and 63% for the oral and ip delivery methods, respectively. In pharmacokinetic studies Zotiraciclib shows moderate to high systemic clearance (relative to liver blood flow), high volume of distribution (>0.6 L/kg), oral bioavailability of 24%, ~4 and 37% in mice, rats and dogs, respectively; and extensive tissue distribution in mice.

相关产品：Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Epigenetics Compound Library  |  Immunology/Inflammation Compound Library  |  JAK/STAT Compound Library  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Stem Cell Signaling Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  AG490  |  Ro-3306  |  Upadacitinib  |  Seliciclib  |  Flavopiridol  |  NVP-2  |  SNS-032  |  AZD-5438  |  Kenpaullone  |  AT9283  |  GSK 3 Inhibitor IX  |  AUZ 454  |  Gandotinib  |  XL413 hydrochloride  |  KW-2449  |  CGP60474  |  Lestaurtinib  |  Wogonin  |  CVT-313  |  NG 52  |  BMS-265246  |  (R)-CR8 trihydrochloride  |  Cucurbitacin I  |  Oclacitinib maleate  |  JANEX-1  |  R547  |  PHA-767491 hydrochloride  |  CDK12-IN-3  |  KH-CB19

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。